Tevogen Bio (NASDAQ:TVGN) Price Target Cut to $5.00 by Analysts at D. Boral Capital

Tevogen Bio (NASDAQ:TVGN) had its price objective trimmed by D. Boral Capital from $10.00 to $5.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.00.

Tevogen Bio Price Performance

NASDAQ TVGN opened at $0.41 on Thursday. Tevogen Bio has a 1 year low of $0.38 and a 1 year high of $1.92. The company has a market capitalization of $81.30 million, a PE ratio of -2.18 and a beta of -0.86. The company has a fifty day moving average of $0.66 and a 200 day moving average of $0.95.

Tevogen Bio (NASDAQ:TVGN) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. Nuveen LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 90,253 shares of the company’s stock, valued at approximately $97,000.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.